Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Income (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Income for 16 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 117.04% to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 million through Dec 2025, up 394.64% year-over-year, with the annual reading at $15.1 million for FY2025, 394.64% up from the prior year.
  • Net Income for Q4 2025 was $3.8 million at Gyre Therapeutics, down from $5.9 million in the prior quarter.
  • The five-year high for Net Income was $51.6 million in Q2 2022, with the low at -$101.0 million in Q4 2023.
  • Average Net Income over 5 years is -$8.0 million, with a median of $2.2 million recorded in 2024.
  • The sharpest move saw Net Income plummeted 453.2% in 2021, then soared 359.42% in 2022.
  • Over 5 years, Net Income stood at -$20.4 million in 2021, then plummeted by 41.21% to -$28.8 million in 2022, then crashed by 250.76% to -$101.0 million in 2023, then surged by 77.77% to -$22.4 million in 2024, then skyrocketed by 117.04% to $3.8 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at $3.8 million, $5.9 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.